Mechanism of Action

Roxadustat (FG-4592, ASP1517, Anatomical Therapeutic Classification (ATC) code B03XA05) is an orally administered small molecule drug that prevents the enzymatic degradation of HIF-1α by inhibiting the PHD enzymes. In consequence, the hematocrit rises and hemoglobin concentrations increase.

Indication

Roxadustat is indicated for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD). Build, train, & validate predictive machine-learning models with structured datasets. Avoid life-threatening adverse drug events & improve clinical decision support.